Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of non-mutated neoantigens presented by TAP-deficient tumors

16 Aug 2018

Abstract excerpt

Most T cell–based immunotherapies of cancer depend on intact antigen presentation by HLA class I molecules (HLA-I). However, defects in the antigen-processing machinery can cause downregulation of HLA-I, rendering tumor cells resistant to CD8+ T cells. Previously, we demonstrated that a unique category of cancer antigens is selectively presented by tumor cells deficient for the peptide transporter TAP, enabling a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30115740
DOI: 10.1084/jem.20180577

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of non-mutated neoantigens presented by TAP-deficient tumorsPMID 30115740Read ↗

Tumor neoantigens: building a framework for personalized cancer immunotherapy.Semantic proximity Read ↗

Progress in Neoantigen Targeted Cancer ImmunotherapiesSemantic proximity Read ↗

Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens.Semantic proximity Read ↗

Identification and Targeting of Mutant Peptide Neoantigens in Cancer ImmunotherapySemantic proximity Read ↗

Proteogenomic analysis unveils the HLA Class I presented immunopeptidome in melanoma and EGFR mutant lung adenocarcinomaSemantic proximity Read ↗

Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants.Semantic proximity Read ↗

Deciphering the tumor-specific immunopeptidome <i>in vivo</i> with genetically engineered mouse modelsSemantic proximity Read ↗

Tumor Antigens beyond the Human Exome.Semantic proximity Read ↗

Characterization of CD8+ T-cell responses to non-anchor-type HLA class I neoantigens with single amino-acid substitutions.Semantic proximity Read ↗

Deciphering the tumor-specific immunopeptidome in vivo with genetically engineered mouse modelsSemantic proximity Read ↗

The repertoire of human tumor-associated epitopes — identification and selection of antigens and their application in clinical trialsSemantic proximity Read ↗

Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.